Cloud Pharmaceuticals: The In Silico Therapeutics Company
Cloud Pharmaceuticals is changing the way drugs are discovered and developed. The worldwide pharmaceutical industry is in need of new drugs that target smaller market segments, are developed faster, and have novel IP, greater drug safety, efficacy, and affordability. Patent protection is expiring for many "blockbuster" medicines and pharmaceutical companies are losing billions to generic competition. But replacing those patented drugs with another blockbuster is unlikely.
Cloud Pharmaceuticals designs new drugs and drug candidates and accelerates the development process by implementing new, innovative cloud computing technology in place of traditional methods. We manage development of multiple assets through an extensive network of partners. This reduces cost, decreases development time, and creates novel molecules with therapeutic value.
Our drug discovery and development implementation consists of in silico drug design process called Quantum Molecular Design that uses high-performance cloud computing resources, followed by immediate preclinical optimization and rapid development toward Investigational New Drug (IND) and Phase 1. We have a growing pipeline including central nervous system (CNS), cancer, inflammation, lipid metabolism, and rare disease indications, among others.
-
Industry
-
Pharmaceutical Manufacturing
-
Company size
-
11-50 employees
-
Headquarters
-
Research Triangle Park, NC
-
Type
-
Privately Held
-
Founded
-
2009
-
Specialties
-
Drug Discovery Partnerships, New Drug Development, and Intellectual Property Protection
